Clinical Trial · NCT00831857

VEGF Imaging in Renal Cell Carcinoma

Overview

The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with sunitinib or bevacizumab plus interferon in patients with RCC. 89Zr-bevacizumab PET imaging will be regarded a promising biomarker if the target for treatment (VEGF) can be visualised and if uptake changes after institution of treatment.

Sponsor

University Medical Center Groningen

Contacts

Sjoukje F. Oosting, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00831857

Eligibility

Inclusion

locally advanced irresectable or metastatic renal cell cancer
women of childbearing potential must use effective contraception
no surgery in the last 4 weeks
no clinically significant cardiovascular events or disease during the last 12 months
no treatment with bevacizumab or another monoclonal antibody with anti-angiogenic properties in the last 4 months
clear cell histology component
not pregnant or nursing
no treatment with a tyrosine kinase inhibitor during the last 4 weeks
no uncontrolled hypertension
measurable disease with x-ray or CT scan, at least one site of disease must be unidimensionally measurable as follows: X-ray \> 20 mm, Spiral CT scan \> 10 mm, non-spiral CT scan \> 20 mm
no untreated brain metastases (CT or MRI not necessary in the absence of symptoms)
absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Exclusion

Exclusion criteria not yet provided.